A pro-life evangelical preacher is leading a campaign to give an experimental treatment to terminally ill baby Charlie Gard.
The Reverend Patrick Mahoney flew to the UK from the US last week to act as a self-appointed spokesman for the Gard family, leading to concerns he is exploiting the case for political gain.
The 63-year-old, who is director of the Christian Defence Coalition and a pastor at the Church on the Hill in Washington DC, said he met with a senior White House official before leaving the US, The Telegraph reported.
Don ald Trump has offered to help baby Charlie, saying he would be “delighted” to help him secure treatment in the UK after courts ruled his life-support machine should be turned off.
Rev Mahoney said he was keeping the US President updated on events in London, The Telegraph reported.
The pro-life pastor has previously been jailed for violating an order banning him from demonstrating in front of abortion clinics in Texas.
Rev Mahoney claimed he was initially prevented from praying at Charlie's bedside. In a Facebook post he claimed it was a "victory" when he was allowed into the intensive care ward, saying: "Let's believe for a miracle and that Great Ormond Street Hospital would continue do the right thing".
The High Court ruled on Monday that Charlie's parents, Connie Yates and Chirs Gard, should be given the chance to present new evidence their son should be given the treatment.
Charlie suffers from a rare mitochrondrial disease, which doctors at Great Ormond Street Hospital say has left him with severe brain damage and muscle weakness.
The European Court of Human Rights had previously rejected an appeal from by the couple to take the baby to the US for treatment after doctors said it would not improve the quality of their son’s life.
Charlie, who was born on 4 August 2016, inherited the defective RRM2B gene leaving him with severe brain damage and unable to open his eyes, move his limbs or breathe without a machine.
Ms Yates and Ms Gard want to try nucleoside therapy, a new treatment that has been used on around a dozen patients in the US with other mitochondial diseases.
Mr Justice Francis, who heard the case in the High Court, said he may not be able to make a final decision on Thursday.
